Thursday, November 12, 2026
23 C
Bengaluru

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry Needed

For decades, Indian pharma has won by playing the volume game—generics, cost arbitrage, regulatory stamina, scale. That model built giants. It also hit a ceiling.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

Topics

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

The Innovator’s Gene and the Generic’s Promise

A medicine must first be discovered. It must then...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...
spot_img

Related Articles

spot_imgspot_img